93 related articles for article (PubMed ID: 17074379)
1. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1.
Lakhashe SK; Kulkarni SS; Thakar MR; Ghate MV; Paranjape RS
Virology; 2007 Mar; 359(2):295-301. PubMed ID: 17074379
[TBL] [Abstract][Full Text] [Related]
2. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.
Rademeyer C; Moore PL; Taylor N; Martin DP; Choge IA; Gray ES; Sheppard HW; Gray C; Morris L; Williamson C;
Virology; 2007 Nov; 368(1):172-81. PubMed ID: 17632196
[TBL] [Abstract][Full Text] [Related]
3. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates.
Haynes BF; Ma B; Montefiori DC; Wrin T; Petropoulos CJ; Sutherland LL; Scearce RM; Denton C; Xia SM; Korber BT; Liao HX
Virology; 2006 Feb; 345(1):44-55. PubMed ID: 16242749
[TBL] [Abstract][Full Text] [Related]
4. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
[TBL] [Abstract][Full Text] [Related]
6. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
Donners H; Davis D; Willems B; van der Groen G
J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
[TBL] [Abstract][Full Text] [Related]
7. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
Beirnaert E; Nyambi P; Willems B; Heyndrickx L; Colebunders R; Janssens W; van der Groen G
J Med Virol; 2000 Sep; 62(1):14-24. PubMed ID: 10935983
[TBL] [Abstract][Full Text] [Related]
9. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype.
Walker PR; Cilliers T; Choge IA; Taylor N; Cohen SS; Morris L
J Med Virol; 2006 Oct; 78(10):1262-8. PubMed ID: 16927278
[TBL] [Abstract][Full Text] [Related]
10. Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India.
Makhdoomi MA; Singh D; Nair Pananghat A; Lodha R; Kabra SK; Luthra K
Virology; 2016 Dec; 499():105-113. PubMed ID: 27643887
[TBL] [Abstract][Full Text] [Related]
11. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
[TBL] [Abstract][Full Text] [Related]
12. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases.
Davis D; Donners H; Willems B; Vermoesen T; Heyndrickx L; Colebunders R; van der Groen G
J Med Virol; 2003 Nov; 71(3):332-42. PubMed ID: 12966537
[TBL] [Abstract][Full Text] [Related]
13. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India.
Prakash SS; Andrabi R; Kumar R; Lodha R; Kabra SK; Vajpayee M; Luthra K
Arch Virol; 2012 Sep; 157(9):1797-801. PubMed ID: 22674340
[TBL] [Abstract][Full Text] [Related]
14. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
[TBL] [Abstract][Full Text] [Related]
16. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
Gray ES; Moore PL; Pantophlet RA; Morris L
J Virol; 2007 Oct; 81(19):10769-76. PubMed ID: 17634239
[TBL] [Abstract][Full Text] [Related]
17. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children.
Prakash SS; Chaudhary AK; Lodha R; Kabra SK; Vajpayee M; Hazarika A; Bagga B; Luthra K
Viral Immunol; 2011 Oct; 24(5):409-13. PubMed ID: 22004138
[TBL] [Abstract][Full Text] [Related]
18. Genetic diversity of primary HIV-1 isolates and their sensitivity to antibody-mediated neutralization.
Gordon CJ; Delwart EL
Virology; 2000 Jul; 272(2):326-30. PubMed ID: 10873775
[TBL] [Abstract][Full Text] [Related]
19. Neutralization diversity of HIV-1 Indian subtype C envelopes obtained from cross sectional and followed up individuals against broadly neutralizing monoclonal antibodies having distinct gp120 specificities.
Mullick R; Sutar J; Hingankar N; Deshpande S; Thakar M; Sahay S; Ringe RP; Mukhopadhyay S; Patil A; Bichare S; Murugavel KG; Srikrishnan AK; Goyal R; Sok D; Bhattacharya J
Retrovirology; 2021 May; 18(1):12. PubMed ID: 33990195
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.
Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P
Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
